- Home
- ARR vs AVDL Comparison
ARR vs AVDL Comparison
Compare ARR & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARR | AVDL |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | ARR | AVDL |
|---|---|---|
| Price | $18.24 | $21.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $18.17 | ★ $19.14 |
| AVG Volume (30 Days) | ★ 4.0M | 1.5M |
| Earning Date | 02-12-2026 | 03-02-2026 |
| Dividend Yield | ★ 15.59% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | $116,798,000.00 | ★ $248,517,000.00 |
| Revenue This Year | $296.22 | $65.47 |
| Revenue Next Year | $99.47 | $30.88 |
| P/E Ratio | $28.39 | ★ N/A |
| Revenue Growth | N/A | ★ 79.88 |
| 52 Week Low | $13.18 | $6.38 |
| 52 Week High | $19.31 | $23.57 |
Technical Indicators
Market Signals| Indicator | ARR | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 52.57 | 59.43 |
| Support Level | $18.09 | $21.51 |
| Resistance Level | $18.66 | $21.65 |
| Average True Range (ATR) | 0.37 | 0.07 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 16.13 | 52.50 |
Price Performance
Historical ComparisonAbout ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.